Arrakis Therapeutics website screenshot

Arrakis Therapeutics

Arrakis Therapeutics is a clinical-stage biopharmaceutical company pioneering RNA-targeted small molecules (rSMs) — orally available small-molecule medicines designed to bind directly to RNA and reach targets long considered undruggable. Its rSM Platform and rSM Toolkit industrialize the discovery and development of these medicines across proprietary and partnered programs, with a lead candidate addressing the root cause of Type 1 Myotonic Dystrophy (DM1). Based in Waltham, Massachusetts, the company is backed by Canaan Partners. This profile is part of the API Evangelist network; Arrakis Therapeutics does not currently publish a public developer API, SDK, or documentation surface.

Arrakis Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceutical, RNA, and Drug Discovery.

Arrakis Therapeutics’ developer surface includes engineering blog, support, and 2 more developer resources.

🌐 Visit website 📡 Source on GitHub
8.8/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiotechnologyPharmaceuticalRNADrug DiscoveryGenetic MedicineSmall MoleculesLife Sciences

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 8.8/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 1.3 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/arrakis-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Arrakis Therapeutics Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support
Support

Company 2

The organization behind the API

Website
Website
 Blog
Blog

Source (apis.yml)

apis.yml Raw ↑ 
aid: arrakis-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/arrakis-therapeutics.png
name: Arrakis Therapeutics
description: Arrakis Therapeutics is a clinical-stage biopharmaceutical company pioneering RNA-targeted small molecules (rSMs)
  — orally available small-molecule medicines designed to bind directly to RNA and reach targets long considered undruggable.
  Its rSM Platform and rSM Toolkit industrialize the discovery and development of these medicines across proprietary and partnered
  programs, with a lead candidate addressing the root cause of Type 1 Myotonic Dystrophy (DM1). Based in Waltham, Massachusetts,
  the company is backed by Canaan Partners. This profile is part of the API Evangelist network; Arrakis Therapeutics does
  not currently publish a public developer API, SDK, or documentation surface.
url: https://raw.githubusercontent.com/api-evangelist/arrakis-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Biotechnology
- Pharmaceutical
- RNA
- Drug Discovery
- Genetic Medicine
- Small Molecules
- Life Sciences
apis: []
common:
- type: DomainSecurity
  url: security/arrakis-therapeutics-domain-security.yml
- type: Website
  url: https://www.arrakistx.com
- type: Blog
  name: News & Press Releases
  url: https://arrakistx.com/news/press-releases/
- type: Support
  name: Contact
  url: https://arrakistx.com/contact/
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence